Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice. / Lu-Nguyen, Ngoc; Ferry, Arnaud; Schnell, Frederick J; Hanson, Gunnar J; Popplewell, Linda; Dickson, George; Malerba, Alberto.

In: Human Molecular Genetics, 10.06.2019.

Research output: Contribution to journalArticle

E-pub ahead of print


  • Accepted Manuscript

    Accepted author manuscript, 1 MB, PDF document

    Embargo ends: 10/06/20


Duchenne muscular dystrophy (DMD) is a rare genetic disease affecting 1 in 3500-5000 newborn boys. It is due to mutations in the DMD gene with a consequent lack of dystrophin protein that leads to deterioration of myofibres and their replacement with fibro-adipogenic tissue. Out-of-frame mutations in the DMD gene can be modified by using antisense oligonucleotides (AONs) to promote skipping of specific exons such that the reading frame is restored and the resulting protein produced, though truncated, is functional. We have shown that AONs can also be used to knock down myostatin, a negative regulator of muscle growth and differentiation, through disruption of the transcript reading frame, and thereby enhance muscle strength. In young mdx mice, combined dystrophin and myostatin exon skipping therapy greatly improved DMD pathology, compared to the single dystrophin skipping approach. Here we show that in aged (> 15-month old) mdx mice, when the pathology is significantly more severe and more similar to the one observed in DMD patients, the effect of the combined therapy is slightly attenuated but still beneficial in improving the disease phenotype. These results confirm the beneficial outcome of the combination approach and support its translation into DMD clinical trials.

Original languageEnglish
Article numberddz125
JournalHuman Molecular Genetics
Early online date10 Jun 2019
Publication statusE-pub ahead of print - 10 Jun 2019
This open access research output is licenced under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

ID: 34025333